The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
Katherine M. Bell-McGuinn
No relevant relationships to disclose
Heidi J. Gray
No relevant relationships to disclose
Gini F. Fleming
Research Funding - AbbVie
Mihaela C. Cristea
No relevant relationships to disclose
Diane M. Medina
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Hao Xiong
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Matthew W. Dudley
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Martin Dunbar
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Vincent L. Giranda
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Yan Luo
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Mark D. McKee
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Lainie P. Martin
No relevant relationships to disclose